Need for Innovative Therapies

Innovative oncology drugs with new mechanisms of action (MOA) are already available for adult cancers and can be more effective than traditional drugs in several refractory malignancies. The field of drug development is currently expanding beyond well-studied areas like signalling pathways, to target patient’s immune system, as well as their unique genetic profile and metabolism. However, despite recent EU regulatory initiatives that changed the landscape of paediatric drug development in Europe for the better, access to innovative therapies remains insufficient and slow for children and adolescents with cancer.

This is why introducing safe and innovative treatments into standard care is a priority for all groups involved or working in the field of childhood cancers, in order to ensure the best possible care and outcomes for all children and adolescents with cancer in Europe.



For more information, please contact
You can tweet using #ACCELERATEplatform